
Research team
Dr. Nasser B. Alsaleh
MSc, PhD · Associate Professor of Pharmacology and Toxicology
College of Pharmacy, King Saud University, Riyadh 11451
Office 1A-08 — Lab 1B-68, Building 23
nbalsaleh@ksu.edu.sa · +966 11 806 3275
KSU faculty profile · Google Scholar · ORCID
Background
Professional Summary
Dr. Nasser Alsaleh is a faculty member in the Department of Pharmacology and Toxicology at the College of Pharmacy, King Saud University. He earned a master’s degree in Pharmaceutical Sciences from the University of Alberta (Edmonton, Canada) and a doctoral degree in Toxicology from the University of Colorado (Denver, United States).
His research is primarily focused on the safety of engineered nanomaterials, particularly those used in biomedical applications and nanomedicine. His work has contributed to understanding the molecular mechanisms driving the interaction and toxicity of engineered nanomaterials in immune cells, including the mast cell, and the impact of nanomaterials on cellular homeostasis at subtoxic exposure levels.
The overarching goal of Dr. Alsaleh’s research is to better understand the toxicological consequences of engineered nanomaterials at the cellular and molecular levels, ultimately to inform safety regulation and unravel novel therapeutic interventions. He has authored and co-authored over 30 peer-reviewed articles and received multiple awards, including the Heim Award (Harold C. Heim Endowment) in recognition of his research and scholastic achievement during his doctoral studies.
Research Interests
- Molecular toxicity of drugs and environmental toxicants
- Safety of engineered nanomaterials
- Molecular interactions between nanomaterials and immune cells
- Therapeutic implications of nanomaterials at the molecular level
Research Goals
- Elucidate the molecular mechanisms of nanomaterial–bio interactions
- Understand the impact of nanomaterials on cellular homeostasis at subtoxic concentrations
- Understand the impact of nanomaterials in contexts of susceptibility, such as co-exposures and co-disease
- Use nanomaterials to understand fundamental cellular processes and identify novel therapeutic targets
Active now
Current Projects
Assessing the safety of novel polymeric nanomaterials on macrophages.
Understanding the impact of gold and silver nanoparticles in cellular senescence within the context of cancer.
Investigating the toxicity of nano-vanadium on macrophages, with a focus on the impact of shape.
Investigating the impact of iron oxide nanomaterials on neuronal function and differentiation at subtoxic concentrations.
Assessing the impact of nanoplastics on basic cellular function.
Training and supervision
Graduate and PharmD Students
Current
Fahad Alhabshan (PharmD, 2024–present). Training in the lab ahead of starting his own project on the toxicity of nano-vanadium in RAW 264.7 cells, with a particular interest in how particle shape affects internalisation and toxicity.
Noura Alnqer (MSc, Toxicology). Carrying out experiments for her thesis project investigating the role of gold and silver nanomaterials in cancer cell senescence.
Previous
Emad Alshehri and Sultan Alghamdi (PharmD, 2023–24). Investigated the impact of imeglimin on RAW 264.7 cells, demonstrating a wide safety margin.
Anas Aljarbou (MSc, Toxicology). Completed his thesis on the molecular immunotoxicity of ZnO-doped MnO nanoparticles, assessing their safety and delineating the mechanisms of toxicity following exposure in RAW 264.7 cells. His work was published in Pharmaceuticals.
Areej Alotaibi (MSc, Toxicology, defended January 2022). Investigated the synergistic response of combining zinc oxide or silver nanoparticles with conventional antibiotics against clinical isolates of MDR bacteria from Saudi hospitals, determining the best combinations and dosing against different strains. Her work was published in Antibiotics, and she won the Best Research Poster Award at the KAUST Research Conference (Thuwal, 2022).
Abdullah Almutairi and Fahad Aldajani (PharmD, 2021–22). Investigated the impact of nanomaterials at subtoxic concentrations on RAW 264.7 cells, and won the best poster award at the College of Pharmacy Research Day (2022).
Selected Publications
For a complete list, see Google Scholar or ORCID.
- Alshamrani AA, Salman SB, Alsaleh NB, Assiri MA, Almutairi MM, Almudimeegh S, Alwhaibi A, As Sobeai HM. miRNA-driven sensitization of breast cancer cells to Doxorubicin treatment following exposure to low dose of Zinc Oxide nanoparticles. Saudi Pharm J. 2024;32(11):102169.
- Alotaibi AM, Alsaleh NB, Aljasham AT, Tawfik EA, Almutairi MM, Assiri MA, Alkholief M, Almutairi MM. Silver nanoparticle-based combinations with antimicrobial agents against antimicrobial-resistant clinical isolates. Antibiotics. 2022;11(9):1219.
- Alsaleh NB, Mendoza RP, Brown JM. Exposure to silver nanoparticles primes mast cells for enhanced activation through the high-affinity IgE receptor. Toxicol Appl Pharmacol. 2019;382:114746.
- Persaud I, Shannahan JH, Raghavendra AJ, Alsaleh NB, Podila R, Brown JM. Biocorona formation contributes to silver nanoparticle induced endoplasmic reticulum stress. Ecotoxicol Environ Saf. 2019;170:77-86.
- Alsaleh NB, Minarchick VC, Mendoza RP, Sharma B, Podila R, Brown JM. Silver nanoparticle immunomodulatory potential in absence of direct cytotoxicity in RAW 264.7 macrophages and MPRO 2.1 neutrophils. J Immunotoxicol. 2019;16(1):63-73.
- Johnson M, Alsaleh N, Mendoza RP, Persaud I, Bauer AK, Saba L, Brown JM. Genomic and transcriptomic comparison of allergen and silver nanoparticle-induced mast cell degranulation reveals novel non-immunoglobulin E mediated mechanisms. PLoS One. 2018;13(3):e0193499.
- Alsaleh NB, Persaud I, Brown JM. Silver nanoparticle-directed mast cell degranulation is mediated through calcium and PI3K signaling independent of the high affinity IgE receptor. PLoS One. 2016;11(12):e0167366.